OGT expands NGS cancer panel offering

Tuesday 3 November 2020
Applications:
Product types:
Miseq_run_v1_large

Oxford, UK – 03 November 2020. Oxford Gene Technology (OGT), a Sysmex Group Company, has today announced the expansion of its SureSeq™ range of next generation sequencing (NGS) panels to facilitate the interrogation of genes involved in breast and ovarian cancer, and myeloid disorders. The two new panels include a comprehensive 70-gene myeloid panel and a 7-gene breast and ovarian cancer panel that incorporates copy number variation (CNV) detection. Both have been designed based on the most recent literature and with input from recognised cancer experts to detect key variants and so help advance cancer research.

The SureSeq Pan-Myeloid panel builds upon OGT’s established position as a frontrunner in developing predesigned and customisable NGS panels for myeloid disorders. Based on the latest research, the new panel includes 70 key genes implicated in a wide range of myeloid disorders, including acute myeloid leukaemia (AML), myeloproliferative neoplasms (MPNs) and myelodysplastic syndrome (MDS).

Facilitated by OGT’s expert bait design and complimentary Interpret NGS analysis software, the SureSeq Pan-Myeloid panel provides excellent coverage uniformity to detect clinically relevant single nucleotide variants (SNVs) and indels down to 1% variant allele frequency (VAF). The panel includes genes such as CEBPA, JAK2, CALR and MPL, as well as covering regions containing hard-to-detect structural variants such as FLT3-ITDs and KMT2A-PTDs. It provides researchers with a single NGS approach to get a comprehensive picture of the key genes involved in myeloid disorders.

For comprehensive detection of abnormalities, including CNVs, in key genes implicated in breast and ovarian cancer, OGT now offers the SureSeq Breast Cancer + CNV panel. Full interrogation of the BRCA genes traditionally requires multiple tests to find indels, SNVs and CNVs. Saving both time and cost, the new SureSeq Breast Cancer + CNV panel simplifies this process with a single assay that detects all these variants and offers 100% concordance with multiplex ligation-dependent probe amplification (MLPA). In addition to BRCA1 and BRCA2, the new panel also targets ATM, TP53, CHEK2, PALB2, and PTEN, and is able to detect CNVs ranging from single exons to full gene deletions and duplications in these genes as well. For customers interested in a larger breast or ovarian cancer panel OGT offers customisation through the SureSeq myPanel™ range of pre-optimised panel content, which can be added to the Breast Cancer + CNV Panel.

“These two new NGS panels highlight our commitment to providing comprehensive assays for research into cancer genetics with the most up-to-date content based on input from our customers,” said John Anson, CEO at OGT. “Our long-standing expertise in hybridisation enrichment, bait design and NGS analysis software means that we can deliver highly reliable ways of finding abnormalities, even in difficult-to-sequence genes where other assays struggle. Furthermore, the fact that we offer a complete NGS solution consisting of library preparation kits, sequencing panels and popular, intuitive analysis software provides an additional layer of convenience and confidence—our products consistently deliver the reliable, reproducible data quality that our customers need.”

For more information, please visit www.ogt.com/ngs_products.

 

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

 

Editor’s notes

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitrodiagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.

For more information on the Company, please visit our website at www.ogt.com

CytoSure™, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. Cytocell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.